MLN8237 ( alisertib ) and its role in peripheral T-cell lymphoma.

about

Aurora A's Functions During Mitotic Exit: The Guess Who Game

P2860

Q26770572-0E41F898-E413-409D-AE12-D9AB7C9B05DF

P2860

MLN8237 ( alisertib ) and its role in peripheral T-cell lymphoma.

Item

http://www.wikidata.org/entity/Q38260926

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

MLN8237 ( alisertib ) and its role in peripheral T-cell lymphoma.

@en

type

Item

label

MLN8237 ( alisertib ) and its role in peripheral T-cell lymphoma.

@en

prefLabel

MLN8237 ( alisertib ) and its role in peripheral T-cell lymphoma.

@en

P1476

MLN8237 ( alisertib ) and its role in peripheral T-cell lymphoma.

@en

P2093

Doraid Alrifai

http://www.w3.org/2001/XMLSchema#string

Ruth Pettengell

http://www.w3.org/2001/XMLSchema#string

P2860

Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma.

Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma.

Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study

Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.

Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.

Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma.

Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.

Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas

Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients.

P304

1731-1736

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.2014.972501

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-10-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25323772

http://www.w3.org/2001/XMLSchema#string

MLN8237 ( alisertib ) and its role in peripheral T-cell lymphoma.

about

P2860

P2860

MLN8237 ( alisertib ) and its role in peripheral T-cell lymphoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698